Cognition Therapeutics, Inc. (CGTX) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 9, 2022 7:00 AM EDTOngoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimers DiseasePositive Preliminary Data for Dry AMD Program Presented at ARVO 2022Proteomics Data from SPARC read out at AAIC
PURCHASE, N.Y., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) (the Company or Cognition), a clinical-stage biopharmaceutical company engaged in the discovery... More
